The Global Ovarian Cancer Diagnostics Market was valued at USD 1.05 Billion in 2024 and is projected to reach USD 1.44 Billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 3.50% during the forecast period (2024–2032). This growth is driven by rising cancer prevalence, increasing awareness of early detection, and technological advancements in biomarker testing and genomic diagnostics across healthcare systems worldwide.
As precision medicine transforms oncology care, diagnostic companies are developing innovative solutions for early ovarian cancer detection and personalized treatment planning. This blog profiles the Top 10 Companies in the Ovarian Cancer Diagnostics Industry—spanning diagnostic test developers, imaging specialists, and molecular biology pioneers revolutionizing women’s cancer care.
🔟 1. Roche Diagnostics
Headquarters: Basel, Switzerland
Key Offering: cobas® and Elecsys® biomarker testing platforms
Roche leads the market with its automated immunoassay systems and companion diagnostics. Their CA 125 II test (Elecsys®) remains the gold standard for ovarian cancer monitoring, while emerging technologies explore multi-marker panels for early detection.
Innovation Focus:
- Development of HE4 biomarker assays
- Liquid biopsy research through Foundation Medicine acquisition
- AI-powered imaging analysis tools
Download FREE Sample Report: Ovarian Cancer Diagnostics Market – View in Detailed Research Report
9️⃣ 2. Abbott Laboratories
Headquarters: Chicago, Illinois, USA
Key Offering: ARCHITECT CA 125 and HE4 assays
Abbott provides critical immunoassay instruments and reagents for ovarian cancer diagnosis and monitoring. Their automated systems enable high-throughput testing with consistent accuracy across global laboratories.
Innovation Focus:
- Multiplex testing development
- Point-of-care testing solutions
8️⃣ 3. Siemens Healthineers
Headquarters: Erlangen, Germany
Key Offering: IMMULITE® biomarker tests, advanced imaging systems
Siemens combines diagnostic testing with its market-leading ultrasound, CT, and MRI imaging solutions for comprehensive ovarian cancer evaluation. Their Atellica® solution automates immunoassay workflows.
Innovation Focus:
- AI-enhanced imaging diagnostics
- Automated laboratory solutions
7️⃣ 4. Thermo Fisher Scientific
Headquarters: Waltham, Massachusetts, USA
Key Offering: BRCA genetic testing, NGS panels, diagnostic antibodies
Thermo Fisher provides comprehensive genomic and proteomic solutions for ovarian cancer stratification. Their Oncomine™ portfolio enables tumor profiling while diagnostic antibodies support laboratory-developed tests.
Innovation Focus:
- Expanding hereditary cancer testing menu
- Liquid biopsy assay development
Download FREE Sample Report: Ovarian Cancer Diagnostics Market – View in Detailed Research Report
6️⃣ 5. Quest Diagnostics
Headquarters: Secaucus, New Jersey, USA
Key Offering: Ova1® blood test, hereditary cancer panels
Quest provides clinical laboratory testing services including their FDA-cleared Ova1 test that evaluates five biomarkers to assess ovarian cancer risk in women with pelvic masses.
Innovation Focus:
- Multi-omics testing approaches
- Telemedicine integration for test access
5️⃣ 6. Hologic, Inc.
Headquarters: Marlborough, Massachusetts, USA
Key Offering: 3D ultrasound systems, ThinPrep® liquid biopsy
Hologic provides diagnostic imaging solutions and specimen collection systems used in ovarian cancer evaluation. Their 3D automated breast ultrasound technology has applications in gynecologic oncology.
Innovation Focus:
- Advanced imaging biomarkers
- Minimally invasive diagnostic tools
4️⃣ 7. Myriad Genetics
Headquarters: Salt Lake City, Utah, USA
Key Offering: myRisk Hereditary Cancer test, BRACAnalysis CDx®
Myriad specializes in genetic testing for hereditary cancer risk assessment, including BRCA1/2 testing that informs ovarian cancer prevention and treatment decisions.
Innovation Focus:
- Polygenic risk score development
- Precision medicine partnerships
3️⃣ 8. Bio-Rad Laboratories
Headquarters: Hercules, California, USA
Key Offering: BioPlex® immunoassay systems, quality controls
Bio-Rad provides diagnostic instruments, reagents, and quality control materials essential for ovarian cancer biomarker testing in clinical laboratories worldwide.
Innovation Focus:
- Multiplex biomarker validation
- Automated workflow solutions
2️⃣ 9. Fujirebio Diagnostics
Headquarters: Tokyo, Japan
Key Offering: HE4 EIA test, Lumipulse® G systems
Fujirebio pioneered the HE4 biomarker for ovarian cancer and continues developing novel immunoassays. Their tests support the ROMA algorithm for malignancy risk assessment.
Innovation Focus:
- Biomarker discovery programs
- Algorithm-based diagnostics
1️⃣ 10. Epigenomics AG
Headquarters: Berlin, Germany
Key Offering: DNA methylation-based cancer tests
Epigenomics develops blood-based epigenetic tests for early cancer detection. Their ovarian cancer program explores novel DNA methylation markers to improve screening efficacy.
Innovation Focus:
- Early-stage detection biomarkers
- Non-invasive diagnostic technologies
Get Full Report Here: Ovarian Cancer Diagnostics Market – View in Detailed Research Report
🔬 Outlook: The Future of Ovarian Cancer Diagnostics
The ovarian cancer diagnostics market is undergoing significant transformation with next-generation technologies improving early detection rates and therapeutic decision-making.
💡 Key Trends Shaping the Market:
- Expansion of multi-modal testing combining biomarkers, imaging, and genetics
- Development of non-invasive liquid biopsy techniques
- Integration of AI in imaging analysis and risk prediction models
- Growing adoption of molecular profiling for targeted therapies
📊 Market Projections by Segment:
- Biomarker tests maintain largest revenue share through 2032
- Genetic testing shows highest growth potential at 6.3% CAGR
- North America dominates regional markets with 38% revenue share
🚀 Emerging Opportunities:
- Minimal residual disease detection technologies
- Commercialization of early detection blood tests
- Expansion of screening programs in high-risk populations
Get Full Report Here: Ovarian Cancer Diagnostics Market – View in Detailed Research Report
The companies profiled above represent the technological vanguard in ovarian cancer diagnostics, driving innovations that promise to improve survival rates through earlier detection and personalized treatment approaches.